Antiangiogenic therapy and dermatology: A review

Drugs of Today

Volumn 33, Issue 10, 1997, Pages 687-696

  Arbiser, Jack L ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; DITHRANOL; FUMAGILLIN; GLUCOCORTICOID; INTERFERON; INTERLEUKIN 12; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; RETINOID; THALIDOMIDE; THALLIUM; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR ALPHA; VITAMIN D DERIVATIVE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ENDOTHELIUM CELL; HEMANGIOMA; HUMAN; METASTASIS INHIBITION; MOLECULAR CLONING; MOLECULAR WEIGHT; NONHUMAN; PSORIASIS; REVIEW;

EID: 0031474032     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Folkman, J. Tumor angiogenesis: Therapeutic implications. New Engl J Med 1971, 285: 1182-98.
2. Arbiser, J.L., Moses, M.A., Fernandez, C.A. et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997, 94: 861-6.
3. O'Reilly, M.S., Holmgren, L. et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79: 315-28.
4. O'Reilly, M.S., Boehm, T., Shing, Y. et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1987, 88: 277-85.
5. Hanahan, D., Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86: 353-64.
6. Tseng, S., Pak, G., Washenik, K., Pomeranz, M.K., Shupack, J.L. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996, 35: 969-79.
7. Lenz, W. Thalidomide and congenital abnormalities. Lancet 1962, 1: 45.
8. Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A., Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J Exp Med 1991, 173: 699-703.
9. Corral, L.G., Muller, G.W., Moreira, A.L. et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996, 2: 506-15.
10. 1 acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci USA 1996, 93: 7552-6.
11. Sampaio, E.P., Kaplan, G., Miranda, A. et al. The influence of thalidomide on the clinical and immunological manifestation of erythema nodosum leprosum. J Infect Dis 1993, 168: 408-14.
12. Koch, H.P. Thalidomide and congeners as anti-inflammatory agents. Prog Med Chem 1985, 22: 165-242.
13. Schmahl, H.J., Dencker, L., Plum, C., Chahoud, I., Nau, H. Stereoselective distribution of the teratogenic thalidomide analog EM12 in the early embryo of marmoset monkey, Wistar rat, and NMRI mouse. Arch Toxicol 1996, 70: 749-56.
14. D'Amato, R.J., Loughnan, M.S., Flynn, E., Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91: 4082-5.
15. MacNicol, A.M., Muslin, A.J., Williams, L.T. Raf-1 kinase is essential for early Xenopus development and mediates the induction of mesoderm by FGF. Cell 1993, 73: 571-83.
16. Ginnsburg, H.M., Nixon, C.E. Thallium poisoning. JAMA 1932, 93: 1076-7.
17. Thyresson, N. Experimental investigation on thallium poisoning in the rat. Acta Dermatol Venerol 1951, 31: 3-27.
18. Tjalve, H., Nilsson, M., Larsson, B. Thallium-201: Autoradiography in pigmented mice and melanin-binding in vitro. Acta Pharmacol Toxicol 1982, 51: 147-53.
19. Fenster, M.S., Feldman, M.D., Camarano, G. et al. Correlation of adenosine thallium 201 perfusion patterns with markers for inducible ischemia. Am Heart J 1997, 133: 406-12.
20. Karnofsky, D.A., Ridgway, L.P., Patterson, P.A. Production of achondroplasia in the chick embryo with thallium. Proc Soc Exp Biol Med 1950, 73: 255-9.
21. Arbiser, J.L., Alani, R., Flynn, E., Wooten, V., Byers, H.R. Effects of thallium ion on cellular components of the skin. J Dermatol 1997, 24: 147-55.
22. Korting, H.C., Kerscher, M.J., Schafer-Korting, M. Topical glucocorticids with improved benefit/ risk ratio. Do they exist? J Am Acad Dermatol 1992, 27: 87-92.
23. Katz, H.I. Topical corticosteroids. Dermatol Clin 1995, 13: 805-15.
24. Auerbach, R., Auerbach, W. Regional differences in the growth of normal and neoplastic cells. Science 1982, 215: 127-34.
25. Lebwohl, M., Abel, E., Zanolli, M., Koo, J., Drake, L. Topical therapy for psoriasis. Int J Dermatol 1995, 34: 673-84.
26. Elder, J.T., Fisher, G.J., Lindquist, P.B. et al. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 1989, 243: 811-4.
27. Detmar, M., Brown, L.F., Claffey, K.P. et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994, 180: 1141-6.
28. Gille, J., Swerlick, R.A., Caughman, S.W. Transforming growth factor a induced transcriptional activation of the vascular permeability factor gene requires AP-2 dependent DNA binding and transactivation. EMBO J 1997, 16: 750-9.
29. Finzenkeller, G., Marme, D., Weich, H.A., Hug, H. Platelet-derived growth factor induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res 1992, 52: 4821-3.
30. Diamond, M.I., Miner, J.N., Yoshinaga, S.K., Yamamoto, K.R. Transcription factor interactions: Selectors of positive or negative regulation from a single DNA element. Science 1990, 249: 1266-72.
31. Clark, S.D., Kobayashi, D.K., Wlegus, H.G. Regulation of the expression of tissue inhibitor of matrix metalloproteinases and collagenases by retinoids and glucocorticoids in human fibroblasts. J Clin Invest 1987, 80: 1280-8.
32. Takahashi, K., Mulliken, J.B., Kozakewich, H.P., Rogers, R.A., Folkman, J., Ezekowitz, R.A. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994, 93: 2357-64.
33. Muller, K., Huang, H.S., Wiegrabe, W. Antipsoriatic anthrones with modulated redox properties. 10-thio-Substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of keratinocyte growth, 5-lipoxygenase, and the formation of 12 S-HETE in mouse epidermis. J Med Chem 1996, 39: 3132-8.
34. Muller, K., Gawlik, I. Novel 10-substituted antipsoriatic anthrones as inhibitors of epidermal 12-lipoxygenase and lipidperoxidation in membranes. Biochem Pharmacol 1995, 50: 2077-83.
35. Bedord, C.J., Young, J.M., Wagner, B.M. Anthralin inhibition of mouse epidermal arachidonic acid lipoxygenase in vitro. J Invest Dermatol 1983, 81: 566-71.
36. Gottlieb, A.B., Khandke, L., Krane, J.F., Staiano-Coico, L., Ashinoff, R., Krueger, J.G. Anthralin decreases keratinocyte TGF-α expression and EGF-receptor binding in vitro. J Invest Dermatol 1992, 98: 680-5.
37. Carraway, K.L. III, Soltoff, S.P., Diamonti, A.J., Cantley, L.C. Heregulin stimulates mitogenesis and phosphoinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J Biol Chem 1995, 270: 7111-6.
38. Altiok, N., Altiok, S., Changeau, J.P. Heregulin-stimulated acetylcholine receptor gene expression in muscle: Requirement for MAP kinase and evidence for a parallel inhibitory pathway independent of electrical activity. EMBO J 1997, 16: 717-25.
39. Novick, D., Cohen, B., Rubinstein, M. The human interferon α/β receptor: Characterization and molecular cloning. Cell 1994, 77: 391-400.
40. Horvath, C.M., Stark, G.R., Kerr, I.M., Darnell, J.E. Jr. Interactions between STAT and non-STAT proteins in the interferon-stimulated gene factor 3 transcription complex. Mol Cell Biol 1996, 16: 6957-64.
41. David, M., Chen, H.E., Goelz, S., Lamer, A.C., Neel, B.G. Differential regulation of the α/β interferon-stimulated Jak/STAT pathway by the SH2 domain-containing tyrosine phosphatase SHPTP-1. Mol Cell Biol 1995, 15: 7050-8.
42. Singh, R.K., Gutman, M., Bucana, C.D., Sanchez, R., Llansa, N., Fidler, I.J. Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995, 92: 4562-6.
43. Bielenberg, D.R., Bucana, C.D., Mulliken, J., Folkman, J., Fidler, I.J. Loss of an endogenous negative angiogenic factor in the epidermis overlying hemangioma lesions. Proc Am Assoc Cancer Res 1997, 38: 524.
44. Kirkwood, J., Hunt-Strawderman, M., Ernstoff, M.S. et al. Interferon α2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST-1684. J Clin Oncol 1996, 14: 7-17.
45. El Kassas, H., Kirkwood, J.M. Adjuvant application of interferons. Semin Oncol 1996, 23: 737-47.
46. Cascinelli, N., Bufalino, R., Morabito, A., MacKie, R. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994, 343: 913-4.
47. Zukerberg, L.R., Nickoloff, B.J., Weiss, S.W. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis. Am J Surg Pathol 1993, 17: 321-8.
48. Greenway, H.T., Cornell, R.C., Tanner, D.J., Peets, E., Boedin, G.M. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 1986, 15: 437-43.
49. Thestrup-Pedersen, K., Jacobsen, I.E., Frentz, G. Intralesional interferon-α2b treatment of basal cell carcinoma. Acta Derm Venereol 1990, 70: 512-4.
50. Steinquist, B., Wennberg, A.M., Gisslen, H., Larko, O. Treatment of aggressive basal cell carcinoma with intralesional interferon: Evaluation of efficacy by Mohs surgery. J Am Acad Dermatol 1992, 27: 65-9.
51. Gudas, L.J. Retinoids, retinoid-responsive genes, cell differentiation and cancer. Cell Growth Differ 1992, 3: 655-62.
52. Corbeil, J., Rapaport, E., Richman, D.D., Looney, D.J. Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells. J Clin Invest 1994, 93: 1981-6.
53. Knobler, R.M., Trautinger, F., Radaszkiewicz, T., Kokoschka, E.M., Micksche, M. Treatment of cutaneous T cell lymphoma with combination of low-dose interferon-α2b and retinoids. J Am Acad Dermatol 1991, 24: 247-52.
54. Lingen, M.W., Polverini, P.J., Bouck, N.P. Retinoic acid induces cells cultured from oral squamous cell carcinoma to become anti-angiogenic. Am J Pathol 1996, 149: 247-58.
55. Verma, A.K., Rice, H.M., Shapas, B.C., Boutwell, R.K. Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced ornithine decarboxylase activity in mouse epidermis by vitamin A analogs. Cancer Res 1978, 38: 793-801.
56. Braunhut, S.J., Moses, M.A. Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP). J Biol Chem 1994, 269: 13472-9.
57. 3 and calcipotriol decrease extracellular plasminogen activator activity in cultured keratinocytes. J Invest Dermatol 1993, 101: 706-12.
58. Masuda, S., Strugnell, S., Calverley, M.J., Makin, H.L., Kremer, R., Jones, G. In vitro metabolism of the anti-psoriatic vitamin D analog, calcipotriol, in two cultured keratinocyte models. J Biol Chem 1994, 269: 4794-803.
59. Kragballe, K., Steijlen, P.M., Ibsen, H.H. et al. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study. Arch Dermatol 1995, 131: 556-60.
60. Kragballe, K. Treatment of psoriasis by the topical application of the novel cholecalciferol analog calcipotriol. Arch Dermatol 1989, 125: 1647-52.
61. Kragballe, K., Gjertsen, B.T., De Hoop, D. et al. Double-blind right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991, 337: 193-6.
62. Shokravi, M.T., Marcus, D.M., Alroy, J. et al. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 1995, 36: 83-7.
63. 3 and their combination inhibit angiogenesis induced by non-HPV harboring tumor cell lines. RAR alpha mediates the antiangiogenic effect of retinoids. Cancer Lett 1995, 89: 117-24.
64. Hirata, S., Matsubara, T., Saura, R., Tateishi, H., Hirohata, K. Inhibition of in vitro endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989, 32: 1065-73.
65. Nabors, G.S., Afonso, L.C., Farrell, J.P., Scott, P. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin-12 and pentostam. Proc Natl Acad Sci USA 1995, 92: 3142-6.
66. Sriskawdan, S., Evans, T.J., Cohen, J. Bacterial superantigen-induced human lymphocyte responses are nitric oxide dependent and mediated by IL-12 and IFN-γ. Immunol 1996, 156: 2430-5.
67. Guler, M.L., Gorham, J.D., Hsieh, C.S. et al. Genetic susceptibility to Leishmania. IL-12 responsiveness in Th1 cell development. Science 1996, 271: 984-7.
68. Huang, F.P., Feng, G.J., Lindop, G., Stott, D.I., Liew, F.Y. The role of interleukin-12 and nitric oxide in the development of spontaneous autoimmune disease in MPR/MP-Ipr/Ipr mice. J Exp Med 1996, 183: 1447-59.
69. Voest, E.E., Kenyon, B.M., O'Reilly, M.S., Truitt, G., D'Amato, R.J., Folkman, J. Inhibition of angiogenesis in vivo by interleukin-12. JNCI 1995, 97: 581-6.
70. Luster, A.D., Leder, P. IP-10, a -C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993, 178: 1057-65.
71. Shapiro, S.D., Campbell, E.J., Kobayashi, D.K. et al. Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-γ. J Clin Invest 1990, 86: 1204-10.
72. O'Reilly, M.S., Holmgren, L., Chien, C., Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996, 2: 689-92.
73. Dong, Z., Kumar, R., Yang, X., Fidler, I.J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997, 88: 801-10.
74. Holmgren, L.H., O'Reilly, M., Folkman, J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995, 1: 149-53.
75. Rastinejad, F., Polverini, P.J., Bouck, N.P. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989, 56: 345-55.
76. Dameron, K.M., Volpert, O.V., Tainsky, M.A., Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin 1. Science 1994, 265: 1582-4.
77. Weinstat-Saslow, D.L., Zabrenetsky, V.S., VanHoutte, K. et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994, 54: 6504-11.
78. Sheibani, N., Frazier, W.A. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Natl Acad Sci USA 1995, 92: 6788-92.
79. Levitski, A., Gazit, A. Tyrosine kinase inhibition: An approach to drug development. Science 1995, 267: 1782-8.
80. Cox, A.D., Garcia, A.M., Westwick, J.K. et al. The CAAX peptidomimetic compound B581 specifically blocks farnesylated but not geranyl-geranylated or myristylated oncogenic ras signailing and transformation. J Biol Chem 1994, 269: 19203-6.
81. Kohl, N.E., Orner, C.A., Conner, M.W. et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995, 1: 792-7.
82. Lebowitz, P.F., Davide, J.P., Prendergast, G.C. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 1995, 15: 6613-22.
83. Hu, Q., Klippel, A., Muslin, A.J., Fantl, W.J., Williams, L.T. Ras-dependent induction of cellular response by constitutive active phosphatidylinositol-3-kinase. Science 1995, 268: 100-2.
84. Lengyel, E., Stepp, E., Gum, R., Boyd, D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-H-ras. J Biol Chem 1995, 270: 23007-12.
85. Kaplan, D.,Whitman, M., Schaffhausen, B. et al. Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphoinositol kinase activity. Cell 1987, 50: 1021-9.
86. Winston, L.A., Hunter, T. JAK2, Ras and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. J Biol Chem 1995, 270: 30837-40.
87. Oikawa, T., Shimamura, M. Potent inhibition of angiogenesis by wortmannin, a fungal metabolite. Eur J Pharmacol 1996, 318: 93-6.
88. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, et al. Failure of blood-island formation and vasculogenesis in FLK-1 deficient mice. Nature 1995;376:62-66
89. Fong, G.H., Rossant, J., Gertsenstein, M., Breitman, M.L. Role of the flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376: 66-9.
90. Millauer, B., Shawayer, L.K., Plate, K.H., Risau, W., Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant negative flk-1 mutant. Nature 1994, 367: 576-9.
91. Kim, K.J., Li, B., Winer, J. et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362: 841-4.
92. Strawn, L.M., McMahon, G., App, H. et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996, 56: 3540-5.
93. Ingber, D., Fujita, T., Kishimoto, S. et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990, 348: 555-7.
94. Abe, J., Zhou, W., Takuwa, N. et al. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinase and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protoconcogene expression in vascular endothelial cells. Cancer Res 1994, 54: 3407-12.
95. Koyama, H., Nishizawa, Y., Hosoi, M. et al. The fumagillin analog TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet derived growth factor and insulin-like growth factor-1. Circ Res 1996, 79: 757-64.